Premier Biomedical Announces the Addition of Dr. Ryan C. Fields to Scientific Advisory Board

EL PASO, Texas--(BUSINESS WIRE)--Premier Biomedical, Inc. (OTCBB: "BIEI") announced the addition of Dr. Ryan C. Fields to their Scientific Advisory Board effective immediately. Dr. Fields will report to the Chairman of the Scientific Advisory Board and co-founder of the Corporation, Dr. Mitchell S. Felder, MD, and to the President and CEO, William A. Hartman.

Ryan C. Fields, M.D., F.A.C.S. is an Assistant Professor of Surgical Oncology at Barnes-Jewish Hospital and the Alvin J. Siteman Cancer Center at Washington University School of Medicine in St. Louis, Missouri. He also serves as an Associate Program Director for the General Surgery Residency Program and is Director of Resident Research. Dr. Fields completed his undergraduate studies at the University of Michigan where he was mentored in Cancer Immunology and Biology. He received his MD degree from Duke University and completed a General Surgery Residency at Barnes-Jewish Hospital at Washington University School of Medicine in St. Louis.

After completing a Surgical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center, Dr. Fields joined the faculty at Washington University. His clinical interests include the treatment of primary and secondary/metastatic liver tumors, pancreatic cancer, gastric cancer, sarcoma, and melanoma/skin cancer. His research focuses on the biology and genetics of cancer metastases. Through collaborations with The McDonnell Genome Institute at Washington University and colleagues in the Department of Medical Oncology, Dr. Fields and his team are applying cutting edge genomic techniques to investigate the changes a tumor undergoes from primary malignancy to metastatic disease.

William A. Hartman, President and CEO of Premier Biomedical stated, "Dr. Fields' credentials in oncology and immunology are impressive. We will immediately utilize his experience and knowledge, together with the other distinguished members of our Scientific Advisory Board to guide and expedite the advancement of our R&D programs underway to combat breast and other forms of cancer with our partners at the University of Texas at El Paso (UTEP)."

About Premier Biomedical, Inc.

Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for a wide range of diseases in humans, in collaboration with the University of Texas at El Paso initially targeting the treatment of cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company's R&D efforts are centered in El Paso, TX and their business offices are in Western Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." http://www.premierbiomedicalinc.com/

Safe Harbor Notice

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.

Contacts

Premier Biomedical, Inc.
W. Hartman, 724-633-7033
[email protected]

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.